CLOS
GTHX

Compagnie Lombard Odier SCmA’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-601,591
Closed -$14.5M – 700
2021
Q1 		$14.5M Buy
+601,591
New +$14M 0.32% 65

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Compagnie Lombard Odier SCmA's GTHX Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2021, closing a stake of 601,591 shares — an estimated $14.5M sold.

Compagnie Lombard Odier SCmA first reported a position in GTHX in Q1 2021 and held it in 1 quarter. The position peaked at $14.5M in Q1 2021. 114 funds tracked by Wall St. Rank hold GTHX as of Q2 2021.

  • Compagnie Lombard Odier SCmA reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 601,591 G1 Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $14.5M.
  • Compagnie Lombard Odier SCmA first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's G1 Therapeutics, Inc. Common Stock position peaked at $14.5M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.